- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
AstraZeneca Gets SEC Nod for New Trastuzumab Deruxtecan Indication in HER2-Positive Solid Tumors

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has recommended approval for an additional indication of Trastuzumab Deruxtecan 100 mg powder for concentrate for solution for infusion, developed by AstraZeneca Pharma India Limited.
The decision comes after AstraZeneca presented additional data seeking a waiver of local clinical trials for the new indication. The SEC noted that this proposed use has already been approved in the United States, Canada, and Australia, strengthening the case for its adoption in India.
Following detailed deliberation, the committee recommended approval of the indication “for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment or who have no satisfactory alternative treatment options.”
The approval, however, is subject to AstraZeneca conducting a Phase IV study in India to collect local safety and efficacy data.
The SEC directed AstraZeneca to submit the India-specific Phase IV study protocol within three months of receiving marketing permission for this new indication. This requirement ensures that real-world evidence on Indian patients is generated, complementing global data.
This recommendation marks a significant milestone for AstraZeneca’s oncology portfolio, expanding the accessibility of targeted HER2-directed therapies for patients in India.
Trastuzumab Deruxtecan, an antibody–drug conjugate, has been recognized globally for its efficacy in advanced HER2-positive solid tumors, offering hope to patients with limited treatment options.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751